MedPath
HSA Approval

LYCAN INJECTION 2% W/V

SIN17134P

LYCAN INJECTION 2% W/V

LYCAN INJECTION 2% W/V

November 7, 2024

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantYUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION

INTRAVENOUS, INFILTRATION

Medical Information

C01BB01, N01BB02

Manufacturer Information

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Y.S.P. Industries (M) Sdn. Bhd.

Active Ingredients

Lidocaine Hydrochloride Monohydrate

2% w/v

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

LYCAN INJECTION 2% W/V - HSA Approval | MedPath